The Health Resources and Services Administration issued the long-awaited “mega-rule” intended to define who qualifies for deep discounts on drug prices under the federal 340B program.
After a courtroom victory against Amgen Inc. this summer, the last of the obstacles was removed for the first biosimilar agent—a white blood cell growth factor—to enter the U.S. market.
Cancer researcher Sidney Mirvish died at age 86. His research into nitrosamines and carcinogenesis led to changes in the way lunch meats, hot dogs and sausages were made.
The American Society of Clinical Oncology issued an updated policy statement on genetic and genomic testing for cancer susceptibility.
ECOG-ACRIN opened the NCI-MATCH precision medicine trial, the largest, most scientifically rigorous precision medicine trial in cancer to date.
A federal judge ruled that Amgen Inc. cannot force me to answer questions related to a 2007 story that sparked a class action suit by investors and triggered a change in FDA regulations of erythropoiesis-stimulating agents.
After years of turmoil and plunging morale at MD Anderson Cancer Center, the UT System took what observers describe as an unprecedented step—forming a Shared Governance Committee.
A Story in Mugshots: from left, Jerald Cobbs, former CPRIT chief commercialization officer; Texas Governor Rick Perry; and Travis County District Attorney Rosemary Lehmberg. The indictment of Texas Governor Rick Perry by a Travis County grand jury brings together two complex subplots: The controversy over the Cancer Prevention and Research Institute of Texas, which came into […]
Teva Parenteral Medicines Recalls Adrucil The FDA published a draft guidance for the pharmaceutical industry to ensure that FDA-regulated medications are continually manufactured under strict quality standards.
Carolyn Mary Kaelin, a surgical oncologist in the Women's Cancers Program at Dana-Farber and director of the Breast Clinic at Brigham and Women's Hospital, died July 28, surrounded by loved ones. Kaelin was 54.
